Michael E. Bozik
Corporate Officer/Principal at BIOHAVEN LTD.
Profile
Michael E.
Bozik is currently the President, Chief Executive Officer & Director at Knopp Neurosciences, Inc. He also holds the position of President, Chief Executive Officer & Director at Knopp Biosciences LLC since 2010.
Additionally, he serves as the Chief Executive Officer at Channel Biosciences LLC and as a Director at Life Sciences Pennsylvania, Areteia Therapeutics, Inc., and Biohaven Ltd.
In his former positions, Dr. Bozik worked as the Vice President-Neuroscience Clinical Development at Bristol Myers Squibb Co. and as the Vice President-Global Research & Development at Bayer Healthcare LLC.
He also served as the Chief-Neuro Oncology Division at UPMC Cancer Institute.
Dr. Bozik completed his undergraduate studies at the University of Notre Dame and obtained a doctorate degree from the University of Pittsburgh.
Michael E. Bozik active positions
Companies | Position | Start |
---|---|---|
BIOHAVEN LTD. | Corporate Officer/Principal | - |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Chief Executive Officer | - |
Knopp Biosciences LLC
Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Chief Executive Officer | 2010-12-27 |
Life Sciences Pennsylvania
Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009. | Director/Board Member | - |
Channel Biosciences LLC
Channel Biosciences LLC BiotechnologyHealth Technology Part of Pfizer Inc., Channel Biosciences LLC is an American bioscience company. The company is located in the US. The CEO of the company is Michael E. Bozik. Channel Biosciences was acquired by Biohaven Pharmaceutical Holding Co. Ltd., a subsidiary of Pfizer Inc. from Knopp Biosciences LLC on April 01, 2022 for $1,230.99 million. | Chief Executive Officer | - |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | Director/Board Member | - |
Former positions of Michael E. Bozik
Companies | Position | End |
---|---|---|
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
UPMC Cancer Institute
UPMC Cancer Institute Medical/Nursing ServicesHealth Services UPMC Cancer Institute provides health care and insurance services. The company was founded in 1985 and is headquartered in Pittsburgh, PA. | Corporate Officer/Principal | - |
Bayer Healthcare LLC
Bayer Healthcare LLC Pharmaceuticals: MajorHealth Technology Bayer Healthcare LLC provides healthcare and pharmaceutical medicines. It also provides researching, developing, manufacturing and marketing services for the prevention, diagnosis and treatment of diseases. The company is headquartered in Whippany, NJ. | Corporate Officer/Principal | - |
Training of Michael E. Bozik
University of Notre Dame | Undergraduate Degree |
University of Pittsburgh | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
BIOHAVEN LTD. | Health Technology |
Private companies | 7 |
---|---|
Bayer Healthcare LLC
Bayer Healthcare LLC Pharmaceuticals: MajorHealth Technology Bayer Healthcare LLC provides healthcare and pharmaceutical medicines. It also provides researching, developing, manufacturing and marketing services for the prevention, diagnosis and treatment of diseases. The company is headquartered in Whippany, NJ. | Health Technology |
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Knopp Biosciences LLC
Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Life Sciences Pennsylvania
Life Sciences Pennsylvania Miscellaneous Commercial ServicesCommercial Services Life Sciences Pennsylvania (LSPA) is a trade association that represents various entities in the life sciences industry, including biotechnology, medical device, diagnostic, pharmaceutical, research, and investment companies, as well as service providers. The non-profit company is based in Wayne, PA and has subsidiaries in the United States. The organization unifies innovators in the state to make Pennsylvania a leader in the life sciences industry. Founded in 1989, LSPA aims to create a business and public policy environment that encourages and incentivizes the diverse life sciences economy in Pennsylvania. Christopher P. Molineaux has been the CEO of the company since 2009. | Commercial Services |
UPMC Cancer Institute
UPMC Cancer Institute Medical/Nursing ServicesHealth Services UPMC Cancer Institute provides health care and insurance services. The company was founded in 1985 and is headquartered in Pittsburgh, PA. | Health Services |
Channel Biosciences LLC
Channel Biosciences LLC BiotechnologyHealth Technology Part of Pfizer Inc., Channel Biosciences LLC is an American bioscience company. The company is located in the US. The CEO of the company is Michael E. Bozik. Channel Biosciences was acquired by Biohaven Pharmaceutical Holding Co. Ltd., a subsidiary of Pfizer Inc. from Knopp Biosciences LLC on April 01, 2022 for $1,230.99 million. | Health Technology |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | Health Technology |
- Stock Market
- Insiders
- Michael E. Bozik